Millennium Management LLC cut its stake in shares of OvaScience (NASDAQ:OVAS) by 27.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 290,403 shares of the biotechnology company’s stock after selling 112,149 shares during the quarter. Millennium Management LLC’s holdings in OvaScience were worth $407,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Two Sigma Investments LP purchased a new stake in shares of OvaScience during the fourth quarter valued at $342,000. Deutsche Bank AG grew its holdings in shares of OvaScience by 7,476.4% during the fourth quarter. Deutsche Bank AG now owns 517,693 shares of the biotechnology company’s stock valued at $724,000 after buying an additional 510,860 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of OvaScience by 6,531.3% during the fourth quarter. Renaissance Technologies LLC now owns 782,165 shares of the biotechnology company’s stock valued at $1,095,000 after buying an additional 770,370 shares during the last quarter. 38.71% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:OVAS opened at $0.94 on Friday. OvaScience has a one year low of $0.94 and a one year high of $0.94. The firm has a market capitalization of $33.43 million, a price-to-earnings ratio of -0.72 and a beta of 3.13.
OvaScience (NASDAQ:OVAS) last posted its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.07. OvaScience had a negative net margin of 14,580.87% and a negative return on equity of 58.43%. The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.10 million. equities research analysts anticipate that OvaScience will post -1.21 EPS for the current year.
OVAS has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of OvaScience in a report on Friday, March 16th. ValuEngine raised shares of OvaScience from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
OvaScience, Inc, a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women's fertility.
Want to see what other hedge funds are holding OVAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OvaScience (NASDAQ:OVAS).
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.